
    
      Phase III clinical trial, comparative, open, multicenter, prospectively, with random inflow
      of 78 patients evaluable male patients with erectile dysfunction with IIEF-5 score in between
      13 and 24, corresponding to mild or mild to moderate to evaluate the efficacy and safety as
      well as a possible superiority expressed by the faster onset of action onset of action of
      study medication.
    
  